JP2020528878A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528878A5
JP2020528878A5 JP2019570445A JP2019570445A JP2020528878A5 JP 2020528878 A5 JP2020528878 A5 JP 2020528878A5 JP 2019570445 A JP2019570445 A JP 2019570445A JP 2019570445 A JP2019570445 A JP 2019570445A JP 2020528878 A5 JP2020528878 A5 JP 2020528878A5
Authority
JP
Japan
Prior art keywords
ifn
interferon
cancer
prodrug
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037982 external-priority patent/WO2018236701A1/en
Publication of JP2020528878A publication Critical patent/JP2020528878A/ja
Publication of JP2020528878A5 publication Critical patent/JP2020528878A5/ja
Pending legal-status Critical Current

Links

JP2019570445A 2017-06-20 2018-06-18 がん治療用インターフェロンプロドラッグ Pending JP2020528878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522564P 2017-06-20 2017-06-20
US62/522,564 2017-06-20
PCT/US2018/037982 WO2018236701A1 (en) 2017-06-20 2018-06-18 INTERFERON PRODRUCE FOR THE TREATMENT OF CANCER

Publications (2)

Publication Number Publication Date
JP2020528878A JP2020528878A (ja) 2020-10-01
JP2020528878A5 true JP2020528878A5 (cg-RX-API-DMAC10.html) 2021-05-27

Family

ID=64737368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570445A Pending JP2020528878A (ja) 2017-06-20 2018-06-18 がん治療用インターフェロンプロドラッグ

Country Status (7)

Country Link
US (1) US20200123227A1 (cg-RX-API-DMAC10.html)
EP (1) EP3641829A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020528878A (cg-RX-API-DMAC10.html)
KR (1) KR20200015742A (cg-RX-API-DMAC10.html)
CN (1) CN111050803A (cg-RX-API-DMAC10.html)
CA (1) CA3067539A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018236701A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
US20240076355A1 (en) * 2021-01-14 2024-03-07 AskGene Pharma, Inc. Interferon Prodrugs and Methods of Making and Using the Same
KR20230157448A (ko) * 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
KR20240021943A (ko) * 2021-06-18 2024-02-19 남미 테라퓨틱스, 인크. 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법
EP4387987A2 (en) * 2021-08-18 2024-06-26 Werewolf Therapeutics, Inc. Activatable inteferon polypeptides and methods of use thereof
US20240400633A1 (en) * 2021-09-30 2024-12-05 Orionis Biosciences, Inc. Split human ifn-gamma and tnf-alpha constructs and uses thereof
WO2023060156A2 (en) * 2021-10-08 2023-04-13 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
MX2024004301A (es) * 2021-10-08 2024-04-26 Cytomx Therapeutics Inc Construcciones de citocinas activables y metodos combinados.
US20240067691A1 (en) * 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물
KR20260026098A (ko) * 2023-05-12 2026-02-25 리제너론 파아마슈티컬스, 인크. 인터페론 수용체 길항제 및 이의 용도
EP4750813A1 (en) * 2023-07-25 2026-06-03 TJ Biopharma (Shanghai) Co., Ltd. Masked interferon fusion proteins and uses thereof
WO2025201363A1 (zh) * 2024-03-27 2025-10-02 高雄医学大学 细胞因子阻断抗体及其应用
WO2026158523A1 (en) * 2025-01-24 2026-07-30 Tj Biopharma (Hangzhou) Co., Ltd. Masked multifunctional proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL197568B1 (pl) * 1997-12-19 2008-04-30 Applied Research Systems Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
US20100189727A1 (en) * 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
US8399219B2 (en) * 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Similar Documents

Publication Publication Date Title
ES3053456T3 (en) Interleukin-2-fc fusion proteins and methods of use
US10182984B2 (en) Targeted interferons demonstrate potent apoptotic and anti-tumor activities
JP2024074801A5 (cg-RX-API-DMAC10.html)
Mertens et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC‐91‐GPOH)
Ungerechts et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine
JP2020530298A5 (cg-RX-API-DMAC10.html)
Cicchelero et al. Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer
Chester et al. Engineering antibodies for clinical applications in cancer
Iorgulescu et al. Immunotherapy for glioblastoma: going viral
JP2021500932A5 (cg-RX-API-DMAC10.html)
JP2006500009A5 (cg-RX-API-DMAC10.html)
EP1315742B1 (en) Amino acid substitution mutants of interleukin 13
Touchefeu et al. Radiovirotherapy: principles and prospects in oncology
Larcombe-Young et al. PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer
Öcal et al. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
Tojjari et al. Exploring Glypican-3 as a molecular target in hepatocellular carcinoma: perspectives on diagnosis and precision immunotherapy strategies
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
Yoshikawa et al. Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells
RU2020101640A (ru) Пролекарство интерферона для лечения рака
JP2024531338A (ja) 活性化可能インターフェロンポリペプチド及びその使用方法
Boisgerault et al. Oncolytic virotherapy for human malignant mesothelioma: recent advances
Spitzweg Gene therapy in thyroid cancer
Tsai et al. Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy
Santhosh et al. Role of 18F-FDG PET/CT in the management of a case of autoimmune pancreatitis with extrapancreatic manifestations
Johnson et al. Intracranial response in patients with baseline brain metastases and extensive-stage small cell lung cancer treated with ifinatamab deruxtecan (I DXd) in the IDeate-Lung01 study